WillItSurvive
Pharma and healthcare groups · acquisition pending · India

Manipal Hospitals

manipalhospitals.com ↗

Private Indian hospital network, 49 hospitals, 13,037 beds across 14 states.

Hard to displace
Assessed 30 July 2026 · Evidence as of 30 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 30 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Manipal Health Enterprises IPO listing on BSE/NSE
The call

Manipal's hospital network is hard to replace quickly, but its IPO landed to weak demand and profit dipped as it digests the Sahyadri deal.

Manipal Hospitals owns and operates a network of 49 hospitals with over 13,000 beds and 11,000 doctors across India, providing cancer treatment, heart surgery, organ transplants, and routine care. It is hard to copy quickly because hospitals need government licenses, take years to build, and require trained doctors to staff, but Apollo Hospitals (a bigger rival) is growing faster and making more profit, and artificial intelligence is not a real threat since Manipal already uses robotic surgery tools as an advantage rather than facing them as competition. The stock price is high compared to similar companies, the company just bought another hospital chain and profits fell 15% during the merger, so the main question is whether profits bounce back in the next year or whether the purchase did not work out as planned.

Why
01
AI pressure: None apparent. AI shows up here as robotic surgery tools like MAKO that Manipal buys and offers, not as a threat replacing its beds or doctors. Could AI do the core job? Unlikely.
02
Bigger players: Apollo Hospitals Enterprise. Apollo runs more hospitals and pulled in 2.4x Manipal's FY26 revenue with faster profit growth, competing hospital by hospital. Could a giant copy it? No, they are blocked.
03
What protects it. Licensed beds, doctor networks, and insurer contracts take years to build, so rivals expand slowly even when they have more cash.
What would change this call
Manipal FY27 Q2 results show whether PAT margin recovers from Sahyadri integration drag. Tests if acquisition-led growth model can absorb integration costs without eroding profit.
Apollo Hospitals announces or expands Karnataka/Bangalore capacity in 2026-2027. Would show the market leader directly contesting Manipal's home-state stronghold.
Manipal announces new hospital beds outside Karnataka in FY27 expansion filings. Would show whether the 46-52% Karnataka revenue concentration is actually being diversified.
Key numbers
  • 13,037 licensed beds, 49 hospitals, 14 states (2026-03-31)
  • FY26 revenue roughly Rs 10,336-10,936 crore (2026-03-31)
  • IPO only 45% subscribed by day two (2026-07-30)
Named risks
  • IPO priced at ~85x P/E vs peers' 62 to 68x amid tepid 45% subscription demand. Severity: high
  • Margin pressure and profit decline from Sahyadri Hospitals integration continuing into FY27. Severity: high
  • Karnataka revenue concentration of 46 to 52% exposes company to regional shocks. Severity: medium
  • Post-IPO promoter dilution could shift governance dynamics. Severity: medium
  • Sector-wide regulatory scrutiny of hospital pricing practices, as seen in the Delhi CCI case closed May 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Apollo Hospitals Enterpriselosing toApollo FY26 revenue Rs 25,228cr, +15.7% YoY, net profit +33% YoY, 2.4x Manipal's scale (2026-07-29)
Max Healthcare InstitutecontestingMax market cap ~Rs 1.104 trillion (Nov 2025) rivals Manipal's ~Rs 77,600cr IPO valuation despite smaller footprint
Fortis Healthcare (IHH Healthcare)contestingFortis market cap Rs 61,344 to 77,020cr, comparable scale, EBITDA margin ~23.4% vs Manipal ~25.6% (2026-07-25)
Narayana HealthcontestingNamed alongside Apollo, Fortis, Max as preferred listed healthcare peers by analysts (2026-07-26)
Questions people ask
Is Manipal Hospitals profitable?
Yes. Manipal Health Enterprises reported FY26 net profit in the range of Rs 654.93 crore to Rs 916.52 crore depending on disclosure basis, though one analysis (Upstox, 2026-07-29) shows PAT fell roughly 15% YoY due to Sahyadri acquisition integration costs, versus FY25 profit of Rs 534.7 crore.
Is Manipal Hospitals going public?
Yes, its IPO subscription window ran July 29 to 31, 2026, priced at Rs 560 to 590 per share, raising Rs 9,275 crore at up to a Rs 77,600 crore (about $10.3 billion) valuation. Listing was tentatively scheduled for August 5, 2026 on BSE and NSE.
Who owns Manipal Hospitals?
As of 2025-26, Temasek (via Sheares Healthcare) holds roughly 51 to 59%, Manipal Group founder Dr. Ranjan Pai's entities hold about 30 to 31%, TPG Asia holds 10 to 11%, and Mubadala, Novo Holdings and CalPERS hold roughly 8% combined, per a 2025-11-09 Livemint report.
Could AI replace Manipal Hospitals?
No. Manipal's core business is physical, licensed hospital care across 49 hospitals and 13,037 beds requiring liability-bearing clinical judgment; AI shows up as a tool it deploys, such as MAKO robotic joint replacement used at facilities like Kanakapura Road since October 2025, not a threat displacing its services.
Who is Manipal Hospitals' biggest competitor?
Apollo Hospitals Enterprise, India's largest private hospital chain with about 76 hospitals and FY26 revenue of Rs 25,228 crore (+15.7% YoY) and net profit of Rs 2,002 crore (+33% YoY), roughly 2.4 times Manipal's FY26 revenue of Rs 10,335 to 10,935 crore.
Is Manipal Hospitals stock a good buy after its IPO?
Uncertain. The IPO priced Manipal at roughly 85x P/E versus peers Apollo, Max and Fortis at 62 to 68x, and Day 2 (July 30, 2026) subscription was only about 45% with a thin 2% grey-market premium, signaling investor caution despite strong anchor commitments of Rs 4,167 crore.
Timeline
  • 2026-08-05Manipal Health Enterprises tentatively set to list on BSE and NSE
  • 2026-07-30IPO Day 2 subscription only about 45%, grey market premium near 2%
  • 2026-07-29IPO opens for public subscription, priced Rs 560 to 590 per share
  • 2026-07-28Anchor investors including ADIA, Goldman Sachs, Morgan Stanley commit Rs 4,167 crore
  • 2026-05-23Manipal Robotic Summit in Kolkata claims 3,000+ robotic surgeries performed
  • 2025-10Sahyadri Hospitals acquisition closes for Rs 6,400 crore, beating EQT and Blackstone bids
  • 2025-09-19Draft IPO papers for Rs 8,000 crore issue filed with SEBI
  • 2024-02Temasek sells partial secondary stake to Mubadala, Novo Holdings, CalPERS
  • 2023-04-10Temasek acquires additional 41% stake for about Rs 16,000 crore
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources